Back to Search
Start Over
Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits.
- Source :
- Cancer Medicine; Jan2020, Vol. 9 Issue 1, p94-103, 10p
- Publication Year :
- 2020
-
Abstract
- Objectives: Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiveness thresholds (λ) on individual and population‐level health benefits remains uncharacterized. The current study examined the potential benefits of value‐based pricing by quantifying the incremental net health benefit (INHB) of publicly funded oncology drugs, if funding occurred at manufacturer‐submitted price without value‐based pricing. Methods: Pan‐Canadian Oncology Drug Review (pCODR) submissions were reviewed to identify eligible drug indications from which final economic guidance panel reports were reviewed for incremental costs (ΔC) and quality‐adjusted life‐years (ΔQALY) from manufacturer‐submitted, pCODR lower‐limit (pCODR‐LL) and upper‐limit (pCODR‐UL) re‐analyzed estimates. Annual number of cases in Ontario for each drug indication was obtained from population databases. Annual QALY gain per drug indication was determined by (ΔQALY × cases). Population QALY gain/loss in the absence of value‐based pricing to reference λ was estimated by the INHB: (INHB = [ΔQALY − (ΔC/λ)] × cases). Results: In total, 34 drug indications (4629 cases) were identified. Annual gain in QALYs for the funded drug indications using manufacturer, pCODR‐LL, and pCODR‐UL estimates was 1851, 1617, and 1301, respectively. At a λ $100 000/QALY, funding in the absence of value‐based pricing resulted in loss of 2311, 2519, and 2604 QALYs. This would result in a provincial net annual loss of 460, 902, and 1303 QALYs. Conclusions: Despite an annual gain in QALY per funded drug indication, a net loss in QALY for the province, in the absence of value‐based pricing, was demonstrated. Supportive evidence exists for value‐based pricing toward the promotion of health benefits for the greater population. [ABSTRACT FROM AUTHOR]
- Subjects :
- POPULATION health
REFERENCE pricing
HEALTH promotion
NET losses
DIRECT costing
Subjects
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 9
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Cancer Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 141050646
- Full Text :
- https://doi.org/10.1002/cam4.2694